SHCBP1 and neoplasm: In contrast, γH2AX and p53 expression decreased in A549 and HeLa cells treated with SHCBP1 siRNA combined with docetaxel (DTX) or paclitaxel (PTX) (Fig. 7D), indicating that targeting SHCBP1 combined with DNA-damaging agents enhanced the anti-tumour effect, which might be attenuated when combined with microtubule-toxic drugs.